linjc16/ctgov huggingface dataset:
CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing.

Official Title
-----------------
CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients

Conditions
-----------------
Presence of COVID-19 Compatible CT Abnormalities

Intervention / Treatment
-----------------
* Diagnostic Test: PET-CT of 18F-FDG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient coming to nuclear medicine for 18F-flurodesoxyglucose (FDG) positron emission tomography computed tomography (PET-CT) with suspicion of lung involvement patient affiliated to a social security scheme or equivalent adult patient having been informed of the study Exclusion Criteria: patient with a negative covid 19 test

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analysis of pulmonary lobes | Visual analysis of the pulmonary lobes by calculating a extent score for each patient | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of metabolic activity | Measurement of metabolic activity with SUV max of lung areas with CT abnormalities | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID19, 18F FDG PET, lung infection, CT, seriological tests
Rapid On-site Evaluation of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Samples by Pulmonologists

Study Overview
=================
Brief Summary
-----------------
The study is aimed at verifying if a pulmonologist in training can reliably assess the adequacy of EBUS-TBNA samples from intrathoracic lymphadenopathy after a period of training provided by an experienced pathologist.

Official Title
-----------------
Rapid On-site Evaluation of EBUS-TBNA Samples From Intrathoracic Lymphadenopathy; Can it be Reliably Performed by a Pulmonologist?

Conditions
-----------------
Intrathoracic Lymphadenopathy

Intervention / Treatment
-----------------
* Diagnostic Test: Rapid on-site evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication to sampling of intrathoracic lymphadenopathy based on computed tomography (CT) and/or positron emission tomography (PET)/CT findings Signed informed consent Exclusion Criteria: High risk conditions for the performance of bronchoscopy and endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) High risk condition for deep sedation (ASA 4) Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy with which the pulmonologist will identify inadequate EBUS-TBNA samples | The Outcome 1 will be measured by verifying the agreement between the pulmonologist judgment and the pathologist judgment, the latter being the gold standard | Up to 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy with which the pulmonologist will be able, in case of adequate EBUS-TBNA sample, to assign the specimen to one of the following specific diagnoses: 1) reactive lymph node; 2) malignancy; 3) granulomatous inflammation | The Outcome 1 will be measured by verifying the agreement between the pulmonologist judgment and the pathologist judgment, the latter being the gold standard | Up to 1 week |
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients

Study Overview
=================
Brief Summary
-----------------
Nonadherence to immunosuppression is a leading cause of late graft rejection, chronic rejection and graft failure and it is regarded as a preventable cause of graft loss after solid organ transplantation. The purpose of this study is to evaluate whether mobile application for drug medication can enhance the drug adherence rate.

Official Title
-----------------
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Device: internet mobile application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1 year after kidney transplantation out-patient follow up in Seoul National University Hospital using android smartphone taking Prograf as a main immunosuppressant 15-70 years Exclusion Criteria: patients who cannot use medication event monitoring system multiorgan transplant immunosuppression medication change within 4 weeks of randomization caregiver management of the medication regimen pregnancy patients who can not use mobile application

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control<br>using Medication event monitoring system | |
| Active Comparator: internet mobile application<br>using both mobile internet application and medication event monitoring system | Device: internet mobile application<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adherence rate |  | up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biopsy proven acute rejection rate |  | up to 6 months |
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor

Study Overview
=================
Brief Summary
-----------------
To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may affect imatinib compliance. Our previous retrospective study suggested that severe skin rash induced by imatinib can be managed by systemic steroid without imatinib dose interruption or reduction. This phase II study was conducted to evaluate the efficacy and safety of systemic steroid in GIST patients with imatinib-associated severe skin rash.

Official Title
-----------------
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor

Conditions
-----------------
Gastrointestinal Stromal Tumor(GIST)

Intervention / Treatment
-----------------
* Drug: Prednisone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older, at the time of acquisition of informed consent Histologically confirmed metastatic and/or advanced (unresectable or recurrent) GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene Patients with metastatic and/or advanced (unresectable or recurrent) GISTs, receiving imatinib as adjuvant or neo adjuvant, palliative chemotherapy for pre-or post- operations imatinib-associated severe skin rash which was defined as grade 3 skin rash or grade 2 skin rash with pruritus over grade 2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: prednisone<br>prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop | Drug: Prednisone<br>* Prednisone treatment for severe skin rash induced by imatinib<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment success rate | Treatment success was defined as maintaining imatinib without persistence or recurrence of skin rash requiring 1) additional systemic steroid treatment, and 2) interruption or dose reduction of imatinib. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastrointestinal stromal tumor, skin rash, imatinib
Drug Use Investigation of Gadovist.

Study Overview
=================
Brief Summary
-----------------
The objectives of this study are to investigate the safety and effectiveness of Gadovist.

Detailed Description
-----------------
This is a prospective, non-interventional, continuous submission safety study that includes patients who planned Gadolinium (Gd) contrast enhanced Magnetic Resonance Imaging (MRI) in accordance with approved label. The investigator will have made the choice of Gd enhanced MRI (the decision to use Gadovist according the Japanese Package Insert prior to enrolling the patient in this study). The study period is 3 years. Data analysis period is 1 year. In total, 3300 patients will be recruited. For each patient, data are collected as defined in the case report form (CRF) at the visit for MRI examination (as per investigators routine practice).

Official Title
-----------------
Drug Use Investigation of Gadovist

Conditions
-----------------
Magnetic Resonance Imaging, Image Enhancement

Intervention / Treatment
-----------------
* Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who perform contrast enhanced Magnetic Resonance Imaging (MRI) with Gadovist. Exclusion Criteria: Patients who are contraindicated based on approved label.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BAY86-4875<br>Gadovist administration goup | Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)<br>* Gadovist dosage following summary of product characteristics<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of episodes of adverse events as a measure of safety and tolerability |  | Up to 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of episodes of adverse drug reactions and adverse events | In subpopulations | Up to 3 days | 
| Contrast enhancement | Investigator Discretion as very improved , improved, not changed, degraded, not evaluable. MRI- Magnetic Resonance Imaging | At the time of MRI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Body and extremities, Gadobutrol, Contrast enhancement in the following MR imaging, Brain and spine
Influence of Wrist Taping on Handgrip Strength in Crossfit Athletes

Study Overview
=================
Brief Summary
-----------------
The idea that the use of a wristband can increase the grip strength is old, but without systematic scientific evidence. Most Crossfit practitioners wear wrist bands during training because it is believed that the wristband increases the grip strength of the hand. The aim of this study is to to analyze the influence of the use of the wristband on the maximum force value and on the dynamic resistance of hand hold. A simple blind randomized cross-over trial will be performed.

Official Title
-----------------
Influence of Wrist Taping on Handgrip Strength in Crossfit Athletes - Crossover Randomized Controlled Trial

Conditions
-----------------
Sport Injury, Hand Injury Wrist

Intervention / Treatment
-----------------
* Other: Wrist taping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be an amateur practitioner of the Crossfit modality with at least 6 months of regular sports practice (at least 4 times a week) between 18-40 years old agree to participate in the study and sign the informed consent form (ICF). Exclusion Criteria: active wrist/ arm injury or pain on the day of the test (pain score greater than 3 in 10 for both shoulder, forearm, wrist and / or hand on the VAS pain scale) history of wrist injury (especially fracture or ligament injury) previous wrist surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Sham first (group 1)<br>Performs the first round of test with the sham comparator than with the experimental wrist taping | Other: Wrist taping<br>* Wrist taping as used as standard in CrossFit practice<br>|
| Experimental: Wrist taping first (group 2)<br>Performs the first round of test with the experimental wrist taping than with the sham comparator | Other: Wrist taping<br>* Wrist taping as used as standard in CrossFit practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grip | Mean of the first 3 hand pressures (kg) measured by hand dynamometer | 0 minutes; 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endurance | Percentage (%) of strength measured in the last 3 movements in relation to the first 3 movements | 0 minutes; 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sports
Evaluating the Effect of the VCD on Erectile Function and Penile Length Post RRP

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to perform a randomized prospective study to evaluate whether the vacuum erection device facilitates an earlier return of erectile function post radical prostatectomy. A secondary measure will be to evaluate if the vacuum erection device can help prevent penile shortening.

Official Title
-----------------
Evaluating the Effect of the Vacuum Constriction Device on Erectile Function and Penile Length Post Radical Retropubic Prostatectomy

Conditions
-----------------
Prostatic Neoplasms, Prostatectomy

Intervention / Treatment
-----------------
* Device: ErectAid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing a radical prostatectomy for prostate cancer who are able to attain a partial or full erection preoperatively and are sexually active. Exclusion Criteria: Patients on anticoagulation therapy and those with bleeding diatheses Insufficient manual dexterity of patient or spouse IIEF(International Index of Erectile Function) at baseline < 11, indicating severe erectile dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ErectAid|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to show that flow cytometry can be an accurate tool to help physicians regarding the diagnosis, the SIT decision and the SIT arrest of hymenoptera venom allergy. 75 patients having a story of reaction to hymenoptera venom will be selected for this trial. Blood samples will be analyzed at: inclusion visit, Week 1 visit, Week 3 visit, Week 10 and Week 21 visit.

Official Title
-----------------
Interest of Flow Cytometry for the Diagnosis, the Follow up and SIT Arrest of Hymenoptera Venom Allergy

Conditions
-----------------
Allergy

Intervention / Treatment
-----------------
* Other: flow cytometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (18 - 70 years) Patient being informed and accepting to participate in the study with signature of informed consent Patients having a clinical systematic and local, loco-regional story of reaction to the piqures of hymenopterans. Patients treated by SIT for at least 5 years Patients benefiting from a national insurance health Exclusion Criteria: Children Pregnant woman or who breast-feed Patient under antihistaminic or corticoid for less than 8 days before the blood drawing Protected Patient Patient not having given his agreement after it was informed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1 flow cytometry<br>flow cytometry | Other: flow cytometry<br>* flow cytometry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % CD63 expression on basophil membrane by flow Cytometry |  | Inclusion , Week 1, Week 3, Week 10 and Week 21 visits | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood blocking factors level |  | Week 1, Week 3, Week 10 and Week 21 visits |
Evaluating the Well-being Among Dental Students With Warwick-Edinburg Mental Well-Being Scale

Study Overview
=================
Brief Summary
-----------------
The present study was conducted to measure the mental well-being amongst dental students by using Warwick-Edinburg Mental Well-being Scale (WEMWBS) and investigate factors affecting well-being among dental students.

Detailed Description
-----------------
The survey schedule was planned to be independent of the students' assessment period and the questionnaire was administered to the students when they were attending a lecture together. After the lecture, a researcher explained to the students the purpose of this survey and assured them of confidentiality. Participation in this study was also voluntary, and all participants remained anonymous. The questionnaire was given to all participants after explaining the purpose of the study. The questionnaire included demographic details (age, gender, year of study), social background (parents' education levels, family income, first choice for admission, living accommodation) and lifestyle behaviors (smoking status, presence of regular sport activity and hobby). In addition, Warwick-Edinburg Mental Well-Being Scale was applied to the participants of this study.

Official Title
-----------------
Evaluating the Well-being Among Dental Students With Warwick-Edinburg Mental Well-Being Scale and the Relationship Between Mental Well-being and Socio-demographic Findings

Conditions
-----------------
Well Being

Intervention / Treatment
-----------------
* Other: dental students


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: to be officially registered in the faculty of dentistry, Baskent University Exclusion Criteria: unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 27 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Warwick-Edinburg Mental Well-being Scale | Individuals completing the scale are required to tick the box that best describes their experience of each statement over the past two weeks using a 5-point Likert scale (none of the time, rarely, some of the time, often, all of the time). The Likert scale represents a score for each item from 1 to 5 respectively, giving a minimum score of 14 and maximum score of 70. | day 1 |